DCM
EWTX icon

DAFNA Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

DAFNA Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.22M Buy
226,819
+114,583
+102% +$3.95M 1.76% 16
2026
Q1 		$3.54M Sell
112,236
-47,500
-30% -$1.37M 0.8% 33
2025
Q4 		$3.96M Sell
159,736
-54,000
-25% -$1.08M 0.92% 27
2025
Q3 		$3.47M Sell
213,736
-24,404
-10% -$346K 0.86% 29
2025
Q2 		$3.12M Buy
238,140
+55,000
+30% +$793K 0.86% 28
2025
Q1 		$4.03M Sell
183,140
-4,000
-2% -$105K 1.14% 25
2024
Q4 		$5M Sell
187,140
-40,766
-18% -$1.3M 1.27% 22
2024
Q3 		$6.08M Sell
227,906
-62,291
-21% -$1.24M 1.44% 21
2024
Q2 		$5.23M Sell
290,197
-16,000
-5% -$279K 1.25% 24
2024
Q1 		$5.59M Sell
306,197
-143,187
-32% -$2.28M 1.27% 24
2023
Q4 		$4.92M Sell
449,384
-70,000
-13% -$491K 1.18% 27
2023
Q3 		$2.98M Hold
519,384
– – 0.93% 31
2023
Q2 		$4.03M Sell
519,384
-213,855
-29% -$1.8M 1.1% 28
2023
Q1 		$4.89M Sell
733,239
-33,604
-4% -$311K 1.47% 23
2022
Q4 		$6.86M Sell
766,843
-14,269
-2% -$134K 1.93% 16
2022
Q3 		$7.69M Buy
781,112
+85,153
+12% +$860K 2.07% 15
2022
Q2 		$5.54M Buy
695,959
+339,209
+95% +$2.56M 1.51% 20
2022
Q1 		$3.46M Buy
+356,750
New +$4.59M 0.9% 32

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DAFNA Capital Management's EWTX Position: Q2 2026 in Review

DAFNA Capital Management increased its Edgewise Therapeutics (EWTX) stake by 102% in Q2 2026, buying an estimated $3.95M and bringing the position to 226,819 shares worth $9.22M. The position accounts for 1.76% of the portfolio, ranked #16.

DAFNA Capital Management first reported a position in EWTX in Q1 2022 and has held it in 18 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • DAFNA Capital Management held 226,819 shares of Edgewise Therapeutics worth $9.22M as of Q2 2026.
  • DAFNA Capital Management bought 114,583 Edgewise Therapeutics shares in Q2 2026, an estimated $3.95M.
  • Edgewise Therapeutics made up 1.76% of DAFNA Capital Management's portfolio in Q2 2026, its #16 holding.
  • DAFNA Capital Management first reported a position in Edgewise Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.